[go: up one dir, main page]

DK3180335T3 - Cytokrom-p450-inhibitorer og anvendelser deraf - Google Patents

Cytokrom-p450-inhibitorer og anvendelser deraf Download PDF

Info

Publication number
DK3180335T3
DK3180335T3 DK15832340.2T DK15832340T DK3180335T3 DK 3180335 T3 DK3180335 T3 DK 3180335T3 DK 15832340 T DK15832340 T DK 15832340T DK 3180335 T3 DK3180335 T3 DK 3180335T3
Authority
DK
Denmark
Prior art keywords
cytochrome
inhibitors
Prior art date
Application number
DK15832340.2T
Other languages
English (en)
Inventor
Bijoy Panicker
Original Assignee
Angion Biomedica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angion Biomedica Corp filed Critical Angion Biomedica Corp
Application granted granted Critical
Publication of DK3180335T3 publication Critical patent/DK3180335T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK15832340.2T 2014-08-11 2015-08-11 Cytokrom-p450-inhibitorer og anvendelser deraf DK3180335T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462035596P 2014-08-11 2014-08-11
PCT/US2015/044557 WO2016025424A1 (en) 2014-08-11 2015-08-11 Cytochrome p450 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
DK3180335T3 true DK3180335T3 (da) 2021-08-09

Family

ID=55304533

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15832340.2T DK3180335T3 (da) 2014-08-11 2015-08-11 Cytokrom-p450-inhibitorer og anvendelser deraf

Country Status (11)

Country Link
US (3) US9988374B2 (da)
EP (1) EP3180335B1 (da)
JP (1) JP6578349B2 (da)
CN (2) CN112961149A (da)
AU (1) AU2015301891B2 (da)
CA (1) CA2957785C (da)
DK (1) DK3180335T3 (da)
ES (1) ES2886641T3 (da)
HU (1) HUE055262T2 (da)
IL (1) IL250506B (da)
WO (1) WO2016025424A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2886641T3 (es) 2014-08-11 2021-12-20 Angion Biomedica Corp Inhibidores de citocromo P450 y sus usos
CN107531631B (zh) 2014-12-31 2021-09-03 安吉昂生物医药公司 用于治疗疾病的方法和药剂
EP3307798B2 (en) 2015-06-12 2024-06-05 Transitions Optical, Inc. Alignment compounds
CN107743594B (zh) 2015-06-12 2022-07-01 光学转变公司 配向聚合物

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4631862B1 (da) 1968-10-05 1971-09-17
GB2124211B (en) 1982-06-25 1985-12-24 Zyma Sa Dithio compounds pharmaceutical preparations containing them and their use
GB8713861D0 (en) 1987-06-13 1987-07-15 Beecham Group Plc Compounds
US5308854A (en) 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
ATE167473T1 (de) 1990-08-20 1998-07-15 Eisai Co Ltd Sulfonamid-derivate
TW210334B (da) 1990-12-12 1993-08-01 Ciba Geigy Ag
DE4126277A1 (de) 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
JPH0616638A (ja) 1992-03-30 1994-01-25 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物およびその医薬用途
AU662997B2 (en) 1992-07-03 1995-09-21 Ihara Chemical Industry Co. Ltd. Condensed heterocyclic derivative and weedkiller
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
FR2716192B1 (fr) 1994-02-17 1996-04-12 Rhone Poulenc Agrochimie Dérivés de 2-imidazoline-5-ones fongicides.
US5891916A (en) 1995-06-21 1999-04-06 Takeda Chemical Industries, Ltd. Aromatic hydroxamix acid compounds, their production and use
US5977101A (en) 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US5576349A (en) 1995-11-30 1996-11-19 The General Hospital Corporation Retionoic acid treatment of cardiac arrhythmia
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
UA53649C2 (uk) 1996-06-27 2003-02-17 Янссен Фармацевтика Н.В. N-[4-(гетероарилметил)феніл]гетероариламіни, композиція на їх основі та спосіб її одержання, спосіб одержання сполук (варіанти)
JPH1017549A (ja) 1996-07-02 1998-01-20 Banyu Pharmaceut Co Ltd 二環性芳香族アミジン誘導体
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
ATE529109T1 (de) 1997-12-22 2011-11-15 Bayer Healthcare Llc Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
IL136767A0 (en) 1997-12-22 2001-06-14 Bayer Ag Inhibition of raf kinase using substituted heterocyclic ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
AU2006201959B2 (en) 1997-12-22 2008-09-04 Bayer Healthcare Llc Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
AU4005299A (en) 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
ES2299504T3 (es) 2000-06-21 2008-06-01 F. Hoffmann-La Roche Ag Derivados de benzotiazol para el tratamiento de la enfermedad de alzheimer y de la enfermedad de parkinson.
CN1450989A (zh) 2000-07-07 2003-10-22 塔夫茨大学信托人 7－取代的四环素化合物
JP2004509073A (ja) 2000-07-11 2004-03-25 ユニバーシティ・オブ・メリーランド，　ボルティモア 新規なｃ−４置換レチノイド
DE60117839T2 (de) 2000-09-19 2006-11-23 Institut Curie Pyridinon und pyridinethion-derivate mit hiv-hemmenden eigenschaften
JP2004524289A (ja) 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
US20030199523A1 (en) 2002-02-28 2003-10-23 Snutch Terrance P. Heterocyclic calcium in channel blockers
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
CN1742007A (zh) 2003-01-22 2006-03-01 伊莱利利公司 甾族激素核受体的吲哚衍生物调控剂
GB0314733D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
EP1654236A1 (en) 2003-07-10 2006-05-10 OSI Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome p450 inhibitors
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US7262318B2 (en) 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
US20050288340A1 (en) 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006091897A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
AR056339A1 (es) 2005-05-09 2007-10-03 Astrazeneca Ab Derivados benzoicos
DOP2006000273A (es) 2005-12-08 2007-10-15 Aventis Pharma Inc Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
EP1976835A2 (en) 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007091140A1 (en) 2006-02-06 2007-08-16 Pfizer Products Inc. Substituted phenylsulfamoyl compounds as ppar agonists
CN101041660B (zh) 2006-03-22 2010-05-12 中国科学院化学研究所 1,2-二氢吡啶衍生物、碳苷中间体及其制备方法与应用
MX2008012576A (es) 2006-03-30 2008-10-10 Tibotec Pharm Ltd Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
PT2081937E (pt) 2006-10-23 2012-10-15 Sgx Pharmaceuticals Inc Moduladores de proteína-cinase de triazolo-piridazina
EP2125753A1 (en) 2006-12-29 2009-12-02 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds having crf antagonistic activity
AU2008282728B2 (en) 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use
WO2009067166A2 (en) 2007-11-20 2009-05-28 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
WO2009081246A2 (en) 2007-12-19 2009-07-02 Pfizer Inc. Bicyclic diamines as nicotinic receptor agonists
JP5369854B2 (ja) 2008-04-21 2013-12-18 住友化学株式会社 有害節足動物防除組成物および縮合複素環化合物
WO2010036404A2 (en) 2008-05-09 2010-04-01 University Of Maryland, Baltimore Novel retinamide retinoic acid metabolism blocking agents
GB0811091D0 (en) 2008-06-17 2008-07-23 Cancer Rec Tech Ltd CYP26 Inhibitors
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
JP2011530483A (ja) 2008-08-12 2011-12-22 武田薬品工業株式会社 アミド化合物
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
CA2785898C (en) 2009-12-31 2018-07-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN102153547A (zh) 2010-02-11 2011-08-17 山东轩竹医药科技有限公司 含有并环的噁唑烷酮抗菌素
GB201004739D0 (en) 2010-03-22 2010-05-05 Prosidion Ltd Receptor modulators
WO2011119869A1 (en) 2010-03-24 2011-09-29 Medical University Of South Carolina Compositions and methods for the treatment of degenerative diseases
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
WO2011153192A2 (en) * 2010-06-01 2011-12-08 Angion Biomedica Corp. Cytochrome p450 inhibitors and uses thereof
US20210171515A1 (en) 2010-06-01 2021-06-10 Angion Biomedica Corp. Cytochrome p450 inhibitors and uses thereof
US8791263B2 (en) 2010-09-17 2014-07-29 Osaka University Cortistatin A analog and use thereof
JP5629380B2 (ja) * 2010-12-17 2014-11-19 田辺三菱製薬株式会社 連続芳香環式化合物
WO2012101013A1 (en) 2011-01-28 2012-08-02 Boehringer Ingelheim International Gmbh Substituted pyridinyl-pyrimidines and their use as medicaments
US9091692B2 (en) 2011-02-18 2015-07-28 Shinichiro Isobe Fluorescent dye
US8218718B1 (en) 2011-06-01 2012-07-10 Elekta Ab (Publ) Radiotherapy and imaging methods and apparatus
US20140155381A1 (en) 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
US20140315881A1 (en) 2011-07-29 2014-10-23 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013039140A1 (ja) * 2011-09-14 2013-03-21 第一三共株式会社 縮合へテロ環誘導体
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
US9174980B2 (en) 2012-01-31 2015-11-03 Boehringer Ingelheim International Gmbh Heterocyclic compounds as inhibitors of leukotriene production
WO2013151876A1 (en) 2012-04-04 2013-10-10 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
US20150183772A1 (en) 2012-06-01 2015-07-02 The Board Of Trustees Of The University Of Arkansas Alkylation of azoles
WO2013187496A1 (ja) * 2012-06-15 2013-12-19 田辺三菱製薬株式会社 芳香族複素環化合物
US20160038490A1 (en) 2012-07-18 2016-02-11 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
EP2903615B1 (en) 2012-10-05 2021-04-07 Merck Sharp & Dohme Corp. 5-pyridin-3-yl-2,3-dihydro-1h-indole derivatives as aldosterone synthase (cyp11b2) inhibitors for the treatment of hypertension
ES2619610T3 (es) 2012-10-16 2017-06-26 Janssen Pharmaceutica Nv Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo
JP6251277B2 (ja) 2012-10-16 2017-12-20 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲ−ガンマ−ｔのフェニル結合キノリニルモジュレーター
SMT201700347T1 (it) 2012-10-16 2017-09-07 Janssen Pharmaceutica Nv Modulatori di ror-gamma-t chinolinilici legati a metilene
WO2014093960A1 (en) * 2012-12-16 2014-06-19 Angion Biomedica Corp. Compositions and methods for treating disease
ES2886641T3 (es) 2014-08-11 2021-12-20 Angion Biomedica Corp Inhibidores de citocromo P450 y sus usos
CN107531631B (zh) 2014-12-31 2021-09-03 安吉昂生物医药公司 用于治疗疾病的方法和药剂

Also Published As

Publication number Publication date
AU2015301891B2 (en) 2019-12-05
CN107074841B (zh) 2021-03-26
HUE055262T2 (hu) 2021-11-29
CA2957785C (en) 2023-01-03
US20170247363A1 (en) 2017-08-31
AU2015301891A1 (en) 2017-03-09
IL250506A0 (en) 2017-03-30
US20210253566A1 (en) 2021-08-19
US20180334455A1 (en) 2018-11-22
CN112961149A (zh) 2021-06-15
US10556893B2 (en) 2020-02-11
JP6578349B2 (ja) 2019-09-18
ES2886641T3 (es) 2021-12-20
EP3180335A1 (en) 2017-06-21
JP2017524010A (ja) 2017-08-24
EP3180335A4 (en) 2018-02-21
CA2957785A1 (en) 2016-02-18
CN107074841A (zh) 2017-08-18
US11459319B2 (en) 2022-10-04
EP3180335B1 (en) 2021-05-05
US9988374B2 (en) 2018-06-05
WO2016025424A1 (en) 2016-02-18
IL250506B (en) 2020-08-31

Similar Documents

Publication Publication Date Title
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3521289T3 (da) Mnk-inhibitorer og fremgangsmåder forbundet dermed
DK3193611T3 (da) Mk2-inhibitorer og anvendelser deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3205650T3 (da) Egfr-hæmmer og fremstilling og anvendelse deraf
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3201351T3 (da) Kaloriefrie sødestoffer og fremgangsmåder til syntetisering
DK3172213T3 (da) Makrocykliske kinasehæmmere og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3442972T3 (da) Bromdomænehæmmere
DK3212189T3 (da) Substituerede chromaner og fremgangsmåde til anvendelse deraf
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
LT3177608T (lt) Proteinkinazės c inhibitoriai ir jų naudojimo būdai
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf